An open-label study of the effects of a 24-day regimen of gestodene 60 µg/ethinylestradiol 15 µg on endometrial histological findings in healthy women
Author:
- 1 January 1999
- journal article
- research article
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 4 (sup2) , 3-8
Abstract
Objectives: This open-label, non-comparative study was conducted at a single center to evaluate the effects on the endometrium of a 24-day regimen of a combined oral contraceptive containing gestodene (GTD) 60 µg and ethinylestradiol (EE) 15 µg. Methods: Healthy parous women who were ≥ 18 years old and had had regular menstrual cycles for the prior 3 months were randomly assigned to one of two groups. Subjects in group A underwent endometrial biopsies during the late luteal phase of the pretreatment cycle and between days 15 and 24 of cycle 6. Subjects in group B had biopsies between days 15 and 24 of cycle 3 and during the late luteal phase of the post-treatment cycle. GTD 60 µg/EE 15 µg was taken for the first 24 days of a 28-day cycle, followed by placebo pills for 4 days, for a total of six cycles. Results: Data from 27 women were included in the analyses. Eleven of the 13 evaluable baseline biopsies were classified as secretory. Three of nine subjects with evaluable biopsies at cycle 3 and four of nine subjects with evaluable biopsies at cycle 6 had an atrophic endometrium. Post-treatment biopsies showed a typical secretory endometrium in seven of 11 subjects with evaluable biopsies. Conclusions: The results of this study show that the 24-day regimen of GTD 60 µg/EE 15 µg produced effective endometrial suppression.Keywords
This publication has 14 references indexed in Scilit:
- The use of oral contraceptives and the occurrence of acute myocardial infarction in young womenContraception, 1997
- Oral contraceptives and thrombotic diseases: Impact of new epidemiological studiesContraception, 1996
- Comparative Pharmacology of Newer ProgestogensDrugs, 1996
- A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodeneGynecological Endocrinology, 1996
- A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel, with respect to efficacy, cycle control and toleranceContraception, 1995
- GestodeneDrugs, 1995
- Desogestrel, Norgestimate, and Gestodene: The Newer ProgestinsAnnals of Pharmacotherapy, 1995
- Clinical comparison of two low-dose oral contraceptives, Minulet® and Mercilon®, in women over 30 years of ageContraception, 1994
- New progestogens in oral contraceptionContraception, 1994
- Oral Contraceptives and Cardiovascular DiseaseNew England Journal of Medicine, 1981